Image de couverture de livre

Other causes of neurocognitive impairment than covert hepatic encephalopathy ( CHE ) are very frequent, either alone or associated with CHE , in cirrhotic patients with cognitive complaints

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Philippe Sultanik, Lyes Kheloufi, Apolline Leproux, Charlotte Bouzbib, Sarah Mouri, Antoine Santiago, Damien Galanaud, Vincent Navarro, Mehdi Sakka, Marika Rudler, Nicolas Weiss, Dominique Thabut
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
par: Philippe Sultanik, et autres
Publié: (2024)

Editorial: Quantity is important! Authors' reply
par: Marika Rudler, et autres
Publié: (2024)

Multiple Concomitant Precipitating Factors of Hepatic Encephalopathy Are Associated With a Poor Prognosis in Patients With Cirrhosis Admitted to Intensive Care Unit
par: Marika Rudler, et autres
Publié: (2025)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
par: Jiamei Wang, et autres
Publié: (2024)

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study
par: Maria Mironova, et autres
Publié: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
par: Jianrong Li, et autres
Publié: (2024)

Editorial: Can dietary gluten restriction improve hepatic steatosis?
par: Hariklia Kranidioti, et autres
Publié: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
par: Na‐Ling Kang, et autres
Publié: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
par: Chen‐Pi Li, et autres
Publié: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
par: Jian Wang, et autres
Publié: (2024)

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis
par: Carolyn Singleton, et autres
Publié: (2024)

Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C
par: Nikolaos Papadopoulos, et autres
Publié: (2024)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
par: Matthew J. Townsend, et autres
Publié: (2024)

Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
par: Julian Hercun, et autres
Publié: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
par: Vishnu Girish, et autres
Publié: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
par: Hyeyeon Hong, et autres
Publié: (2024)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
par: Elena Vargas‐Accarino, et autres
Publié: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
par: Nabil Noureddin, et autres
Publié: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
par: Jian Wang, et autres
Publié: (2024)

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
par: Ann T. Ma, et autres
Publié: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
par: Lukas Hartl, et autres
Publié: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
par: Jing Li, et autres
Publié: (2024)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
par: Jung Eun Park, et autres
Publié: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
par: Hye Won Lee, et autres
Publié: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
par: Lisa Sandmann, et autres
Publié: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
par: Philip Vutien, et autres
Publié: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
par: WenXian OuYang, et autres
Publié: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
par: Eiichi Ogawa
Publié: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
par: Jian Wang, et autres
Publié: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
par: Maria Buti, et autres
Publié: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
par: Yen‐Chun Liu, et autres
Publié: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
par: Léa Sequier, et autres
Publié: (2024)

No value of non‐selective beta‐blockers after TIPS‐insertion
par: Anja Tiede, et autres
Publié: (2024)

Editorial: The future of managing drug induced liver injury
par: Amanda Nicoll
Publié: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
par: Vibeke Strande, et autres
Publié: (2024)

CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy
par: Peng Zhang, et autres
Publié: (2025)

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies
par: Jasmohan S. Bajaj, et autres
Publié: (2025)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
par: Ming Liu, et autres
Publié: (2025)

Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population‐Based Cohort Study
par: Samantha Baillie, et autres
Publié: (2025)

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021
par: Mehdi Osooli, et autres
Publié: (2025)